Capricor Therapeutics, Inc.
CAPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133869
No open-market purchases or sales by Capricor Therapeutics, Inc. insiders were filed in the last 90 days; 169 institutions reported holding it in 13F filings for Q2 2026, worth $941.6M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Capricor Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 31 | 1 | 31 | +1 |
| Shares | 2.79M | 4 | 2.74M | −53.5K (−1.9%) |
| Value | $16.8M | $0 | $10.6M | −$6.18M (−36.9%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Capricor Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 28,359 | $109.5K | 0.00% |
| Tower Research Capital LLC (TRC) | 3,674 | $14.0K | 0.00% |
| Belpointe Asset Management LLC | 2,070 | $7.99K | 0.00% |
| Federated Hermes, Inc. | 111 | $428 | 0.00% |
Sold out (3)
Institutions that held Capricor Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Bailard, Inc. | 33,601 | $202.0K |
| BNP Paribas Arbitrage, SA | 100 | $600 |
| Royal Bank of Canada | 4 | $0 |
Not filed for Q4 2022 yet (1)
Institutions that held Capricor Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Wipfli Financial Advisors LLC, | 4 | $0 |